Psoriasis

Two posters presented at the 2023 Fall Clinical Dermatology Conference assessed phase 4 study findings on tildrakizumab in patients with moderate to severe plaque psoriasis.

Posters presented at the 2023 Fall Clinical Dermatology Conference evaluated how label warnings may affect new treatment initiation and real-word switching patterns for patients starting risankizumab.

Two posters presented at the 2023 Fall Clinical Dermatology conference identified common patterns among patients with psoriasis (PsO) and psoriatic arthritis (PsA).

No genes were identified in psoriatic patches that were not also mutated in the patient’s unaffected skin area.

Mona Shahriari, MD, assistant clinical professor of dermatology at Yale University and associate director of clinical trials at Central Connecticut Dermatology, provides on overview of the treatment landscape in patients with skin of color with plaque psoriasis.

This study aimed to evaluate the association between the disease burden of psoriasis and the switching of systemic biologic therapies in patients with both psoriasis and psoriatic arthritis.

Psoriasis status from time of diagnosis to initiation of current treatment was less favorable for patients with mild psoriasis compared with moderate psoriasis, according to one study.

Compared with White patients, Black male patients had a higher prevalence of palmoplantar psoriasis, according to one study.

FDA action is no longer expected in Q3 of 2023.

Psoriasis increases the risk of cutaneous melanoma, according to the findings of a new study.

Decreased coronary flow was associated with severe psoriasis, according to one study.

Patients treated by rheumatologists were more often treated with tumor necrosis factor inhibitors, according to one study.

Telehealth visits were just as effective as in-person visits at managing patients initiating apremilast.

Lower fertility rate and increased risk of pregnancy loss were identified among women with moderate to severe psoriasis, according to a new study.

Patients and physicians often disagree on the patient’s disease severity, creating a relationship barrier and frustration among both parties.

The most severe psoriasis was associated with the lowest blood levels of vitamin D and the greatest affected body surface area.

No significant differences regarding racial backgrounds were found when measuring access to biologics among adult patients with psoriasis living in the United States, according to one study.

Survey responses revealed the rates and times at which patients switched from oral to biologic therapies.

Researchers find a causal relationship between metabolic syndrome (MetS) and its components for increased risk of psoriasis.

Patients who were younger and had more disease-related skin symptoms were more likely to express interest in the intervention.

The study adds to a growing amount of literature documenting the impact of psoriasis on mental health.

People with psoriasis were also more likely to have pulmonary comorbidities compared with those who did not have psoriasis.

Authors describe 3 patients with cancer who were given interleukin-23 (IL-23) inhibitors for psoriasis or immune-related psoriasis.

In these preliminary results from the ongoing POSITIVE study, tildrakizumab was shown to have led to significant improvement for patients who have psoriasis.

Researchers laid out 6 position statements for the technology in this patient population.

However, overall fertility rates of patients with psoriasis were similar to national fertility trends, authors found.

Findings are based on a case-control study carried out in Brazil.

Findings are based on a meta-analysis of 51 studies and 739 pregnancies.

It’s estimated around 20% of patients will discontinue their first course of anti–tumor necrosis factor-α (anti–TNF-α) and rates increase over time